Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
21 hedge funds and large institutions have $25.7M invested in Argos Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 10 closing their positions.
177% more capital invested
Capital invested by funds: $9.3M → $25.7M (+$16.4M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
16% less funds holding
Funds holding: 25 → 21 (-4)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$530K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$305K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$167K |
| 4 |
Bank of New York Mellon
New York
|
+$74.2K |
| 5 |
KeyBank National Association
Cleveland,
Ohio
|
+$48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$734K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$467K |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$257K |
| 4 |
FG
Formula Growth
Montreal,
Quebec, Canada
|
-$162K |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$162K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| – | -$79K | -1,718 | Closed |
|
|
SIP
27
Stoneridge Investment Partners
Radnor,
Pennsylvania
| – | -$55K | -1,182 | Closed |
|
28
New York State Common Retirement Fund
Albany,
New York
| – | -$20K | -436 | Closed |
|
29
First Manhattan
New York
| – | -$2K | -50 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$1K | -15 | Closed |
|
ARGS Hedge Fund Activity: Q1 2016 in Review
21 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q1 2016, worth a combined $25.7M — up 177% from $9.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ARGS and 7 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Wasatch Advisors, adding an estimated $530K. The largest seller was Caisse de Depot et Placement du Quebec (CDPQ), exiting entirely with an estimated $734K sold.
- 21 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q1 2016, down from 25 in Q4 2015.
- Funds reported $25.7M of Argos Therapeutics, Inc. stock for Q1 2016, up 177% quarter-over-quarter.
- 7 funds opened new Argos Therapeutics, Inc. positions in Q1 2016 and 10 closed out, a net change of -3 holders.
- The largest Argos Therapeutics, Inc. buyer in Q1 2016 was Wasatch Advisors, an estimated $530K added.
- The largest Argos Therapeutics, Inc. seller in Q1 2016 was Caisse de Depot et Placement du Quebec (CDPQ), an estimated $734K sold.
Based on aggregated 13F filings for Q1 2016.